MEA Alpha-Glucosidase Inhibitors Market Size
| Study Period | 2018 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2018 - 2022 |
| CAGR | 3.60 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
MEA Alpha-Glucosidase Inhibitors Market Analysis
The Middle-East and Africa Alpha-Glucosidase Inhibitors Market size is estimated at USD 57.37 million in current year, and is expected to reach USD 68.46 million by forecast year, growing at a CAGR of 3.60% during the forecast period.
COVID-19 and diabetes have a significant impact on public health in the Middle East and Africa, as well as elsewhere. Diabetes has been linked to an increased risk of fatal infections and severe infections in COVID-19 patients. Because diabetes is one of the most common health problems in the Middle East and Africa, the current study focused on understanding the epidemiology of COVID-19 in diabetics and the strategies put in place by governments to mitigate its impact. In light of the importance and necessity of the epidemic, countries in the Middle East and Africa have implemented a number of preventative and control measures.
The Middle East and African region have witnessed an alarming increase in the prevalence of diabetes, in recent years, the rate of diabetes is at an all-time high, mainly due to lifestyle changes. Diabetes is associated with many health complications. Patients with diabetes require many corrections throughout the day to maintain nominal blood glucose levels, such as administering additional insulin or ingesting additional carbohydrates by monitoring their blood glucose levels. Over the past few decades, african countries have witnessed a rapid increase in diabetes patients, especially those with type 2 diabetes. Developing countries have more than 70% of the global diabetes population. The africans anticipated to experience considerable growth due to a more geriatric population and rising prevalence of diabetes mainly due to the enhanced stress level, sedentary lifestyles, smoking, and excessive consumption of alcohol that elevates the body's sugar levels have led to the growth of the market.
This is driving the demand for Alpha-Glucosidase Inhibitors Market in Middle-East and Africa, thereby driving the market in focus during the forecast period.
MEA Alpha-Glucosidase Inhibitors Market Trends
Rising Diabetes Prevalence in Middle East and Africa Region
Type-1 diabetes accounts for approximately 10% of diabetes cases in the Middle East and Africa, while type-2 diabetes accounts for 90%. Type-1 diabetes patients must take insulin for the rest of their lives while also eating a healthy diet and exercising regularly. Type-2 diabetes patients must eat healthily, stay physically active, and have regular blood glucose tests. They may also need to take oral medication and insulin to keep their blood glucose levels under control. Diabetes has many complications, including diabetic ketoacidosis and nonketotic hyperosmolar coma. Heart disease, stroke, kidney failure, foot ulcers, and eye damage are all serious long-term complications. Despite extensive research on COVID-19, only a few Middle Eastern and African countries focused on the epidemiology of COVID-19 among diabetic patients and its implications. We emphasize the critical importance of conducting a thorough study to fully understand COVID-19 and its relationship to diabetes in order to develop and implement evidence-based initiatives and policies in the Middle East and Africa.
Therefore, owing to the aforesaid factors, the growth of the studied market is anticipated in the Middle East and Africa region.
Saudi Arabia and Egypt is Expected to Dominate the Middle East and Africa Alpha-Glucosidase Inhibitors Market.
Diabetes is one of the mounting health problems the country is facing. Saudi Arabia is ranked among the top three Middle Eastern and African countries with the highest prevalence of diabetes. Saudi Arabia is aiming to reduce the prevalence of the disease by 10% over the next decade. The government is taking on a number of initiatives to stop the epidemic from spreading, such as taxing sugary drinks, promoting physical fitness, and emphasizing preventative care. The government's focus on combating diabetes and the higher purchasing power of the people in the country may help the market for diabetes drugs, like insulin drugs, during the forecast period.
The government has been working on plans and policies to control the outcome of diabetes. For instance, the Saudi government announced in July 2022 that Saudi Arabia saw growing demand for quality healthcare services spurred by changes, including an increasing and aging population and a growing prevalence of lifestyle diseases such as diabetes and obesity. The government and private sector are involved in working on healthcare entities, certifications, and regulations. The government is taking steps to have 100 percent of Saudi citizens covered by insurance and is working towards ensuring affordability, access, and quality digital healthcare and primary care with cost-effectiveness.
Owing to the aforementioned factors, the market is expected to grow during the forecast period.
MEA Alpha-Glucosidase Inhibitors Industry Overview
The Middle East and Africa alpha-glucosidase inhibitors market studied is highly fragmented by the presence of manufacturers like Bayer, SunPharma, Pfizer, and Takeda etc.
MEA Alpha-Glucosidase Inhibitors Market Leaders
-
Takeda
-
Pfizer
-
Bayer
-
SunPharma
-
Glenmark
*Disclaimer: Major Players sorted in no particular order
MEA Alpha-Glucosidase Inhibitors Market News
- April 2023: A study was planned to move towards drug repurposing by utilizing Food and Drug Administration (FDA)-approved drugs against glucosidase and investigating the molecular mechanisms. The target protein was refined and optimized by introducing missing residues and minimizing clashes to find the potential inhibitor against glucosidase.
- July 2022: The drug pricing regulator, the National Pharmaceutical Pricing Authority (NPPA) of India, fixed the prices of 84 drug formulations, including those used for the treatment of diabetes. According to the order, a single tablet of Voglibose was anticipated to cost Rs 10.47 (USD 0.13), excluding GST.
MEA Alpha-Glucosidase Inhibitors Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Drivers
- 4.3 Restraints
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
-
5.1 Drug
- 5.1.1 Alpha-glucosidase Inhibitors
-
5.2 Geography
- 5.2.1 South Africa
- 5.2.2 Saudi Arabia
- 5.2.3 Oman
- 5.2.4 Egypt
- 5.2.5 Iran
- 5.2.6 Rest of Middle-East and Africa
6. MARKET INDICATORS
- 6.1 Type-1 Diabetes Population
- 6.2 Type-2 Diabetes Population
7. COMPETITIVE LANDSCAPE
-
7.1 Company Profiles
- 7.1.1 Bayer pharma
- 7.1.2 Takeda
- 7.1.3 Pfizer
- 7.1.4 Glenmark pharma
- 7.1.5 Sun pharma
- 7.1.6 Torrent
- 7.1.7 Unichem
- 7.1.8 Hexalag
- *List Not Exhaustive
- 7.2 COMPANY SHARE ANALYSIS
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityMEA Alpha-Glucosidase Inhibitors Industry Segmentation
Inhibitors of alpha-glucosidase prevent the small intestine from absorbing carbohydrates. They compete with one another to prevent the enzymes that change complicated, non-absorptive carbohydrates into simple, absorbable ones. The glucoamylase, sucrase, maltase, and isomaltase enzymes are among them. The Middle East and Africa alpha-glucosidase inhibitors market is segmented by geography (Iran, Saudi Arabia, Egypt, Oman, South Africa, and the rest of the Middle East and Africa). The report offers the value (in USD) and volume (in units) for the above segments. We will provide a segment-wise breakdown (value and volume) for all the countries covered under the table of contents.
| Drug | Alpha-glucosidase Inhibitors |
| Geography | South Africa |
| Saudi Arabia | |
| Oman | |
| Egypt | |
| Iran | |
| Rest of Middle-East and Africa |
MEA Alpha-Glucosidase Inhibitors Market Research FAQs
What is the current Middle East and Africa Alpha-Glucosidase Inhibitors Market size?
The Middle East and Africa Alpha-Glucosidase Inhibitors Market is projected to register a CAGR of 3.60% during the forecast period (2024-2029)
Who are the key players in Middle East and Africa Alpha-Glucosidase Inhibitors Market?
Takeda, Pfizer, Bayer, SunPharma and Glenmark are the major companies operating in the Middle East and Africa Alpha-Glucosidase Inhibitors Market.
What years does this Middle East and Africa Alpha-Glucosidase Inhibitors Market cover?
The report covers the Middle East and Africa Alpha-Glucosidase Inhibitors Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Middle East and Africa Alpha-Glucosidase Inhibitors Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
MEA Alpha-Glucosidase Inhibitors Industry Report
Statistics for the 2024 MEA Alpha-Glucosidase Inhibitors market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. MEA Alpha-Glucosidase Inhibitors analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
